Pediatric acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow in which immature myeloid cells, called myeloblasts, multiply out of control and crowd out normal blood production. It is far less common in children than acute lymphoblastic leukemia, accounting for roughly one in five childhood leukemias, but it is treatable: most children reach remission with intensive chemotherapy, and many are cured.
As a hematologic malignancy, AML sits within the broader picture of leukemia in children. Below I walk through what causes it, how it shows up, how we confirm it, and what treatment actually looks like for a family going through it.
What Is Pediatric Acute Myeloid Leukemia?
Blood cells come from stem cells in the bone marrow. One branch, the myeloid lineage, normally matures into red cells, platelets, and white cells such as neutrophils and monocytes. In AML, a genetic error stops that maturation partway, so the marrow fills with blasts that cannot do the job of mature cells.
The word “acute” matters. Without treatment, AML progresses over weeks, not years. That is why children with suspected AML are usually admitted and started on therapy within days of diagnosis.
Pediatric AML has two age peaks: infancy and the teenage years. It is biologically different from adult AML in some ways, with different common genetic changes, which is why children are treated on pediatric-specific protocols rather than adult ones.
Causes and Risk Factors
For most children, there is no identifiable cause. AML arises from acquired mutations in a single blood-forming cell, and parents did nothing to bring it on. That point deserves saying plainly, because guilt is one of the first things I see in families.
A minority of cases are linked to known risk factors:
- Down syndrome — children with trisomy 21 have a markedly higher risk of myeloid leukemia, particularly in early childhood, and often respond well to gentler regimens.
- Inherited bone marrow failure and predisposition syndromes — such as Fanconi anemia, severe congenital neutropenia, and germline mutations in genes like GATA2 or CEBPA.
- Prior chemotherapy or radiation — certain drugs (alkylating agents and topoisomerase II inhibitors) can cause “therapy-related” AML years later.
- Environmental exposures — high-dose ionizing radiation and benzene are established, though uncommon, causes.
Signs and Symptoms
Symptoms come from what the marrow can no longer make. Low red cells cause tiredness and pallor; low platelets cause bleeding; low normal white cells allow infections to take hold. Parents often describe a child who “just wasn’t themselves” for a few weeks.
| Missing or excess cell | What you may notice |
|---|---|
| Low red cells (anemia) | Fatigue, pale skin, breathlessness, poor appetite |
| Low platelets | Easy bruising, nosebleeds, bleeding gums, pinpoint red spots (petechiae) |
| Low neutrophils | Fevers and infections that keep coming back or will not clear |
| Blasts infiltrating tissues | Bone pain, swollen gums, enlarged liver or spleen, lumps in the skin |
Unexplained bruising is a common trigger for a blood test. Bruises in unusual places, such as over the back, are discussed in our article on leukemia bruises on the spine in children.
How Pediatric AML Is Diagnosed
The first clue is usually a complete blood count (CBC). It may show a high, normal, or low white count, but typically with anemia, low platelets, and blasts visible on the blood smear.
Confirmation requires bone marrow aspiration and biopsy. Under standard criteria, AML is diagnosed when blasts make up at least 20% of marrow cells, or at a lower count if certain defining genetic changes are present. Understanding blasts in leukemia helps make sense of these reports.
The marrow sample then goes through several tests:
- Flow cytometry confirms the blasts are myeloid rather than lymphoid.
- Cytogenetics and FISH look for chromosome changes such as t(8;21), inv(16), or monosomy 7.
- Molecular testing (PCR or sequencing) checks genes such as FLT3, NPM1, and CEBPA.
- Lumbar puncture checks whether leukemia cells are in the spinal fluid.
Why genetics shape treatment
These results sort a child into a risk group. Core-binding factor changes, t(8;21) and inv(16), along with NPM1 mutations, generally predict a better response. Monosomy 7 and FLT3-ITD with a high allelic ratio are usually higher risk. Acute promyelocytic leukemia, defined by t(15;17), is a special subtype treated very differently.
Treatment Options and What to Expect
Treatment is intensive and delivered in phases, usually at a specialist pediatric oncology center.
| Phase | Goal | Typical components |
|---|---|---|
| Induction | Achieve remission (clear blasts from marrow) | Cytarabine plus an anthracycline, sometimes with etoposide; intrathecal chemotherapy |
| Consolidation (intensification) | Eliminate remaining leukemia cells | Further courses including high-dose cytarabine |
| Stem cell transplant | Reduce relapse risk in high-risk disease | Allogeneic hematopoietic stem cell transplant from a matched donor |
| Targeted add-ons | Hit specific leukemia features | FLT3 inhibitors, CD33-directed antibody therapy, all-trans retinoic acid and arsenic for APL |
Unlike childhood ALL, pediatric AML usually has no long maintenance phase. Treatment is shorter but more intense, typically spread over several months with long hospital stays while counts recover.
After each course, doctors check measurable residual disease (MRD), a very sensitive test for leftover leukemia cells. MRD results, together with genetics, help decide whether a child needs a transplant.
Supportive care
Much of the work of AML treatment is keeping a child safe while the marrow is empty. That means red cell and platelet transfusions, prompt antibiotics for fever, antifungal protection, nutrition support, and careful monitoring of the heart because anthracyclines can affect heart muscle. Fever during low counts is treated as an emergency.
Outlook and Recent Advances
Outcomes for pediatric AML have improved considerably over recent decades, largely through better risk grouping, more effective supportive care, and transplant for the right patients. Relapse remains the main challenge, and survival varies widely by genetic subtype.
Newer approaches include targeted drugs for specific mutations, antibody-drug conjugates, reduced-intensity transplant conditioning, and immune therapies under study. Many children are treated on clinical trials, which is standard practice in pediatric cancer care and gives access to the best available protocol.
Survivors need long-term follow-up for late effects, including heart function, growth, fertility, and learning, which is part of routine hematology and oncology aftercare. For the wider context of blood cancers, see our leukemia guide.
When to See a Doctor
Most bruises, fevers, and tired spells in children are harmless. Ask your pediatrician for a blood count if your child has:
- Bruising without injury, or petechiae (tiny flat red dots)
- Persistent paleness and fatigue lasting more than a week or two
- Repeated or unexplained fevers
- Bone pain, especially waking the child at night
- Nosebleeds or gum bleeding that is hard to stop
Seek urgent care for fever with a child already known to have low counts, heavy bleeding, or breathing difficulty.
Frequently Asked Questions
Is pediatric AML curable?
Yes, many children are cured. Most achieve remission with induction chemotherapy, and long-term survival depends heavily on the leukemia’s genetic features and how quickly it responds to treatment. Your child’s team can explain the outlook for their specific subtype.
How is AML different from ALL in children?
ALL arises from lymphoid cells and is far more common in children, while AML arises from myeloid cells. AML treatment is shorter but more intensive, with fewer outpatient maintenance years and a greater role for stem cell transplant.
Did something we did cause my child’s leukemia?
Almost never. The vast majority of cases come from random genetic changes in a single marrow cell. Diet, vaccinations, and ordinary household exposures are not recognized causes.
Will my child need a bone marrow transplant?
Not always. Transplant is generally reserved for high-risk genetics, poor response to early treatment, or relapse. Children with favorable-risk disease are usually treated with chemotherapy alone.
How long does treatment last?
Intensive treatment typically runs over several months, organized into four or five courses. Recovery of blood counts between courses often requires extended hospital stays.
